

Medicines Matter



Medicines
Australia

**An investment for a
healthier tomorrow**

Medicines Matter



Medicines
Australia

An investment for a healthier tomorrow



Review of the National Medicines Policy

Conduct a multi-stakeholder review of the National Medicines Policy to ensure breakthrough treatments and therapies can be effectively accommodated and choice maintained for Australian patients.



Continued practice of a Strategic Agreement

Medicines Australia seeks commitment to the continued practice and delivery of outcomes of a mutually beneficial Strategic Agreement every five years, and the continued execution and implementation of the existing agreement, meeting all deliverables and agreed milestones.



PBS listing within 6 months

Medicines Australia seeks commitment to the listing of all positive PBAC recommendations of a new medicine within six months from agreement on pricing, with improved post PBAC listing processes and agreed timeframes, to be reported on yearly, together with at least annual reporting on the achievement of this metric.



Clinical trial harmonisation

Medicines Australia seeks commitment to take a complete proposal, supported by relevant stakeholders, for clinical trial harmonisation to COAG within the first 12 months of a new government.



Intellectual Property and R&D

Medicines Australia seeks commitment to retain the R&D tax incentive in a form that supports clinical trials and removes the requirement for an intensity threshold for research driven medicines manufacturers and to increase data exclusivity to 10 years.